Rapid cancer diagnosis for patients with vague symptoms: a cost-effectiveness study by Mari, Jones et al.
INTRODUCTION
A cancer diagnosis at an advanced stage 
worsens survival, quality of life, and patient 
experience.1 Furthermore, it increases 
healthcare costs due to more expensive 
treatments, higher toxicity, and symptom 
burden,2 and imposes a high financial 
burden on patients and society. Expediting 
cancer diagnosis and treatment initiation by 
improving patient navigation through complex 
diagnostic pathways is therefore central to 
recent national strategies.3 The National 
Institute for Health and Care Excellence 
(NICE) revised its guidelines to achieve timely 
cancer diagnosis and treatment based on 
‘risk thresholds’ or ‘red flags’.4 If the risk of 
symptoms being caused by cancer is above 
a positive predictive value of 3%, referral to 
the urgent suspected cancer pathway (USC) 
is warranted. However, 50% of patients with 
cancer in UK general practice do not present 
with the red flags required for referral to 
a site-specific suspected cancer pathway.5 
These patients with vague and/or non-
specific symptoms wait a median of 34 days 
longer to diagnosis compared with patients 
presenting with alarm symptoms.5
Recognising that existing guidelines and 
pathways underserve this patient population, 
the Danish ‘three-legged model’6 was adapted 
to provide fast access to multidisciplinary 
diagnostic centres for patients with non-
specific and/or vague symptoms that 
could be due to cancer.7 In Wales, two 
health boards are piloting rapid diagnosis 
centres (RDCs), coordinated through the 
Welsh Cancer Network, to evaluate the 
feasibility, acceptability, effectiveness, and 
cost-effectiveness of these services through 
referral from primary care. The Swansea 
Bay University Health Board (SBUHB) pilot 
RDC opened in June 2017 and runs two half-
day clinics a week with five available clinic 
slots. The current multidisciplinary team 
(MDT) consists of a consultant physician, a 
radiologist, a clinical nurse specialist (CNS), 
and a healthcare support worker (HCSW). 
Management and clinical guidance are 
provided by the RDC coordination manager 
and GP project lead. GPs can refer adults with 
vague and/or non-specific symptoms that 
could be due to cancer but do not meet criteria 
for referral under a USC pathway to the RDC. 
Appointments are usually confirmed within 
48 hours of referral and chest X-ray and 
blood tests are initiated by the GP prior to the 
RDC appointment. Patients are seen at the 
RDC within a week and leave the clinic with 
either a diagnosis and management plan or 
further investigations booked.
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Abstract
Background
A pilot rapid diagnosis centre (RDC) allows 
GPs within targeted clusters to refer adults 
with vague and/or non-specific symptoms 
suspicious of cancer, who do not meet criteria 
for referral under an urgent suspected cancer 
(USC) pathway, to a multidisciplinary RDC clinic 
where they are seen within 1 week.
Aim
To explore the cost-effectiveness of the RDC 
compared with standard clinical practice.
Design and setting
Cost-effectiveness modelling using routine data 
from Neath Port Talbot Hospital, Wales.
Method
Discrete-event simulation modelled a cohort 
of 1000 patients from referral to radiological 
diagnosis based on routine RDC and hospital 
data. Control patients were those referred to a 
USC pathway but then downgraded. Published 
sources provided estimates of patient quality of 
life (QoL) and pre-diagnosis anxiety. The model 
calculates time to diagnosis, costs, and quality-
adjusted life years (QALYs), and estimates the 
probability of the RDC being a cost-effective 
strategy.
Results
The RDC reduces mean time to diagnosis 
from 84.2 days in usual care to 5.9 days if a 
diagnosis is made at clinic, or 40.8 days if 
further investigations are booked during RDC. 
RDC provision is the superior strategy (that is, 
less costly and more effective) compared with 
standard clinical practice when run near or at 
full capacity. However, it is not cost-effective if 
capacity utilisation drops below 80%.
Conclusion
An RDC for patients presenting with vague or 
non-specific symptoms suspicious of cancer 
in primary care reduces time to diagnosis and 
provides excellent value for money if run at 
≥80% capacity.
Keywords
cancer diagnosis; cost-effectiveness; early 
detection of cancer; general practice; non-
specific symptoms; rapid diagnosis centre.
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Although the RDC addresses an important 
unmet need, the additional resources 
and costs required may displace other 
interventions and services for patients with 
cancer. This evaluation is therefore aimed at 
exploring the cost-effectiveness of the RDC 
in its first year of operation compared with 
standard clinical practice, to ensure that the 
RDC is doing more good than harm.
METHOD
Patient-level discrete-event simulation (DES)8 
and decision analytic modelling were used to 
estimate the time from referral to diagnosis 
and the cost-effectiveness of the RDC 
compared with standard clinical practice.
DES models a sequence of events, 
following patients as they move through the 
cancer pathway. It allows resource costs 
and health outcomes to be modelled and is 
utilised widely in healthcare settings to tackle 
issues relating to capacity9 and pathway 
redesign.8,10
The model was implemented in Microsoft 
Excel (2016), Visual Basic for Applications 
(version 7.01), and SIMUL8 Professional. 
Deterministic and probabilistic sensitivity 
analyses (PSA) explored the impact of 
assumptions and uncertainties.
The RDC clinicians validated the modelled 
patient pathways and all assumptions. The 
evaluation followed the NICE reference 
case11 and adhered to Consolidated Health 
Economic Evaluation Reporting Standards 
(CHEERS).12 An NHS and Personal Social 
Services perspective was adopted, following 
patients from referral to radiological 
diagnosis. The model ran over 1 year and 
findings were expressed as costs (in GBP at 
2017 exchange rates) and quality-adjusted life 
years (QALYs). No discounting was applied as 
the time horizon did not exceed 12 months. 
The time horizon of 1 year was chosen to 
reflect the length of the available pilot data 
of the RDC.
Study population
Adults aged ≥18 years in the pilot area 
who were referred by their GP to the RDC 
at Neath Port Talbot Hospital (NPTH) for 
further investigation of non-specific and/or 
vague symptoms that could be due to cancer 
between June 2017 and May 2018 were 
included in the evaluation.
A cohort of 1000 patients was simulated 
based on real-life data of the NPTH RDC 
(for the intervention group) and routinely 
collected records of outcome-matched 
patients within SBUHB, who were referred 
to the USC pathway by their GP but then 
downgraded to the non-urgent pathway 
because of the absence of red-flag symptoms 
(for the control group). This sample size 
of simulated patients was chosen because 
it was sufficiently large to account for the 
variability inherent in the data, yet not so large 
that the model run-time became excessive. 
The number was validated by comparing the 
key modelling summary statistics for varying 
patient numbers (a facility that is available 
on SIMUL8). Data received for analysis were 
fully anonymised with all patient identifiers 
removed. Relevant permissions were in 
place before data release and data matching 
for the control group was performed by 
SBUHB.
Modelled patient pathways
On referral by their GP, patients attended 
the next available RDC clinic slot (Figure 1). 
Clinics began with an MDT meeting where 
current and available historical patient notes 
were discussed. Thereafter, patients saw the 
physician/CNS/HCSW for consultation and 
physical examination followed by a computed 
tomography (CT) scan. Alternatively, patients 
could start with a CT scan, followed by their 
physician/CNS/HCSW appointment. At the 
second MDT meeting all patient findings 
were discussed and the patients were placed 
into one of four categories:
• cancer diagnosis with referral to specialist;
• non-cancer diagnosis;
• no serious pathology found with discharge 
to GP; and
• no diagnosis; continue investigations.
Patients with suspected cancer were 
seen again by the CNS for a 20-minute 
appointment to discuss their diagnosis and 
begin a holistic needs assessment. Patients 
with non-cancer diagnoses or those who 
required further investigations were referred 
to relevant hospital departments. Patients 
with no serious pathology were reassured 
and discharged to their GP. 
How this fits in
Patients presenting in general practice with 
vague or non-specific symptoms suspicious 
of cancer are currently underserved. 
Rapid diagnosis centres (RDCs) seek to 
address the unmet needs of patients who 
do not meet referral criteria to an urgent 
suspected cancer pathway. However, no 
evaluations of the cost-effectiveness of 
these novel services exist. This evaluation 
found that a pilot RDC reduced time to 
diagnosis and provided excellent value 
for money at >80% capacity utilisation 
compared with standard clinical practice.
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Input parameters and data sources
Routinely collected, fully anonymised service 
data from the RDC provided model data inputs. 
The probability of a patient receiving a given 
diagnosis (for both RDC and control groups) 
was obtained from individually analysed RDC 
data. Expert opinion and clinical judgement 
were used where necessary to accurately 
interpret the diagnostic codes. Number of 
days between referral (to either RDC or USC) 
and diagnosis was obtained from RDC and 
hospital records. Distributions were fitted to 
the available data to allow sampling for each 
simulated individual in the model. Healthcare 
resource use was collected routinely for 
RDC patients and NPTH records were 
manually searched for control patients. RDC 
implementation costs included staff costs 
and overheads, and access to endoscopy, 
stationary, postage, consumables, and other 
non-pay items provided by the NPTH Finance 
Department. The number of CT scans 
(including the number of body areas scanned 
for each patient) and other investigative tests 
were recorded routinely and costed using 
published unit costs.13 Hospital records 
were searched for patients who required 
further investigations to identify secondary 
care resource use between RDC attendance 
and diagnosis. Similarly, control patient 
healthcare resource use was obtained from 
hospital records. Secondary care resource 
use was then micro-costed for each patient 
individually using standard unit costs.13 
Primary care resource use for both model 
groups was established by examining the 
GP-reported mean frequency of GP visits in 
the 6 months prior to RDC referral, costed 
using standard unit costs.14 No utility data 
were recorded during the RDC. Therefore, 
a rapid literature review was conducted and 
MEDLINE, PubMed, and NHS Economic 
Evaluation Database were searched following 
a systematic review framework. Search 
terms included ‘suspected cancer diagnosis’, 
‘quality of life pre-diagnosis and post-
diagnosis’, ‘anxiety’, and ‘vague symptoms’ 
(the complete list of search terms (or search 
strategy) can be obtained from the authors 
on request). 
The initial search yielded 2438 results, of 
which 2426 were not relevant for patients 
with vague symptoms, based on a scan of the 
abstracts. Of the remaining 12 papers, three 
were applicable to the evaluation in question 
and reported data on QoL that could be used 
to extrapolate utility values.15–17 However, 
none of these papers reported utilities based 
on responses to the EQ-5D questionnaire, 
which is the preferred patient-reported 
outcome measure used to calculate utilities 
required for health economic evaluation.11 
Because of this lack of EQ-5D results 
in the published literature, utilities were 
extrapolated from the general population18 
with pre-diagnosis anxiety-related 
decrements applied based on relative 
literature values.15–17 Further information and 
a detailed list of input parameters and data 
sources are available from the authors on 
request. 
Analyses
A model-based cost–utility analysis (CUA) of 
the actual RDC provision between June 2017 
and May 2018 assessed the incremental costs 
per QALY gained as a result of the introduction 
of the RDC compared with standard clinical 
practice. QALYs incorporate quantity of 
life and quality of life in one measure. The 
Physician
apppointment
CT scan
2nd MDT
meeting
Reporting
after CT
Outcomes
appointment
Discharge
from RDC
Suspected
cancer
additional CNS
appointment
1st MDT
meeting
Figure 1. Schematic of the patient pathway through the 
rapid diagnosis centre (RDC) in the model intervention 
group. CNS = cancer nurse specialist. CT = computed 
tomography. MDT = multidisciplinary team. 
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incremental cost-effectiveness ratio (ICER) 
resulting from the CUA was compared with 
the willingness-to-pay threshold of £20 000 
per QALY gained as standardised by NICE.11 
A series of deterministic one-way sensitivity 
analyses investigated the impact of changes 
in RDC costs, number of patients per clinic, 
healthcare costs, and alternative utility 
assumptions on the results. PSA calculated 
the probability of the intervention being 
cost-effective at different willingness-to-pay 
thresholds based on 1000 bootstrapping 
iterations drawn from distributions around 
the mean base case values, and these 
probabilities were presented as a cost-
effectiveness acceptability curve.
RESULTS
Between June 2017 and May 2018, 189 
patients attended the RDC. Of these patients, 
46% were male and the mean age was 
70 years (standard deviation [SD] = 12.9 
years; minimum = 26; maximum = 95). Most 
patients presented with unexplained weight 
loss, pain, fatigue, and shortness of breath. 
The final outcomes were categorised into 
four groups: cancer diagnosis with referral to 
specialist (n = 23, 12%), non-cancer diagnosis 
(n = 30, 16%), no serious pathology found 
with discharge to GP (n = 68, 36%), and no 
diagnosis; continue investigations (n = 68, 
36%).
Time to diagnosis
Mean time to diagnosis was 5.9 days (SD = 3.4; 
minimum = 1.0; maximum = 15.0) for RDC 
patients who had a cancer diagnosis, other 
diagnosis, or were discharged. For patients 
requiring further investigations, the mean 
time to diagnosis was 40.8 days (SD = 28.0; 
minimum = 0.0; maximum = 132.0). If outliers 
were removed (that is, 3-month delays for 
four patients needing specialised services), 
this decreased to 33.9 days. Control patients 
waited 84.2 days (SD = 65.3; minimum = 0.0; 
maximum = 657.0) for diagnosis. 
Costs between referral and diagnosis
Total staff costs per half-day clinic were 
calculated as £2640 with CT scan and other 
test costs amounting to £118.21 per patient. 
Healthcare costs accumulated between RDC 
referral or USC downgrade and radiological 
diagnosis were estimated for all outcome 
categories in both model groups. Patients 
diagnosed with cancer or other conditions 
and discharged to their GP with no serious 
pathology found were assumed to only incur 
RDC costs. Any further investigations and all 
control pathways were costed individually. 
Costs are displayed in Table 1 for different 
Table 1. Total healthcare cost between referral and diagnosis
 Mean cost per RDC patient, Cost per control patient,  
Outcome category £ (SD), n = 189 £ (SD), n = 85 Difference, £
1 patient per clinic 
Cancer diagnosis 2758 2397 (2107) 361 
Other diagnosis 2758 871 (688) 1887 
No serious pathology found (discharge) 2758 515 (139) 2243 
No diagnosis (further investigations) 3148 (214) 953 (381) 2195
2 patients per clinic 
Cancer diagnosis 1438 2397 (2107) –959 
Other diagnosis 1438 871 (688) 567 
No serious pathology found (discharge) 1438 515 (139) 923 
No diagnosis (further investigations) 1828 (214) 953 (381) 875
2.78 patients per clinica 
Cancer diagnosis 1068 2397 (2107) –1329 
Other diagnosis 1068 871 (688) 197 
No serious pathology found (discharge) 1068 515 (139) 553 
No diagnosis (further investigations) 1458 (214) 953 (381) 505
3 patients per clinic 
Cancer diagnosis 998 2397 (2107) –1399 
Other diagnosis 998 871 (688) 127 
No serious pathology found (discharge) 998 515 (139) 483 
No diagnosis (further investigations) 1388 (214) 953 (381) 435
4 patients per clinic    
Cancer diagnosis 778 2397 (2107) –1619 
Other diagnosis 778 871 (688) –93 
No serious pathology found (discharge) 778 515 (139) 263 
No diagnosis (further investigations) 1168 (214) 953 (381) 215
5 patients per clinic 
Cancer diagnosis 646 2397 (2107) –1751 
Other diagnosis 646 871 (688) –225 
No serious pathology found (discharge) 646 515 (139) 131 
No diagnosis (further investigations) 1036 (214) 953 (381) 83
aActual mean number of patients seen between June 2017 and May 2018 per clinic. RDC = rapid diagnosis centre. 
SD = standard deviation.
Table 2. Summary of the results of the cost–utility analysis for a 
model cohort of patients, N = 1000
 No RDC RDC Difference (95% CI)
2.78 patients per clinic
  Cost £934 156 £1 207 651 £273 494 (–£445 641 to £747 343)
  QALY 1416 1425 9.20 (–204 to 201)
  ICER (cost per QALY gained) £29 732 
4 patients per clinic
  Cost £934 156 £917 826 –£16 330 (–£713 924 to £448 358)
  QALY 1416 1425 9.20 (–204 to 201)
  ICER (cost per QALY gained) –£1775 (outperforms) 
5 patients per clinic
  Cost £934 156 £785 836 –£148 320 (–£839 771 to £312 218)
  QALY 1416 1425 9.20 (–204 to 201)
  ICER (cost per QALY gained) –£16 124 (outperforms) 
ICER = incremental cost-effectiveness ratio. QALY = quality-adjusted life year. RDC = rapid diagnosis centre. 
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patient numbers per clinic to illustrate the 
effect of capacity on RDC per-patient costs.
Cost-effectiveness
The model base case used actual outcome 
data and costs of the RDC between June 
2017 and May 2018 with a mean number of 
2.78 patients per clinic. During this service 
start-up phase, the RDC was more costly 
and more effective compared with referral 
to USC pathway followed by downgrade with 
an ICER of £29 732 (Table 2). Since July 2018, 
the RDC has run near or at full capacity, 
consistently seeing between four and five 
patients per clinic, with a mean number of 
4.65 patients (93% use of capacity) per clinic 
over the last year, thus outperforming usual 
care (that is, being less costly and more 
effective).
During deterministic sensitivity analysis 
(Table 3), findings were robust to changes 
in utility values and the assumption that 
the pre-diagnosis stage is associated with 
increased anxiety. Findings are sensitive 
to changes in costs and the number of 
patients attending each clinic. As such, due 
to economies of scale, the RDC outperforms 
standard clinical practice with four or five 
patients per clinic, but is not cost-effective 
when only one, two, or three patients are 
seen.
PSA based on the observed 2.78 patients 
per clinic in the RDC start-up phase 
produced a probability of being cost-effective 
of 48.5% at a willingness-to-pay threshold 
of £20 000 (Figure 2). At maximum capacity 
of five patients per clinic, RDC outperforms 
standard clinical practice with a 56.0% 
probability of being cost-effective.
DISCUSSION
Summary
A pilot RDC for patients with vague and/or 
non-specific symptoms suspicious of cancer 
is cost-effective compared with standard 
clinical practice available in Wales (that is, 
referral to USC pathway and subsequent 
downgrade due to the absence of red-flag 
symptoms) when run near or at full capacity. 
Table 3. Summary of one-way sensitivity analyses conducted and 
optimal strategy based on WTP of £20 000
Parameter Change Optimal strategy
Cost of RDC Change number of patients per day RDC (outperforms) 
  from 2.78 to 5 
Cost of RDC Change number of patients per day RDC (outperforms) 
  from 2.78 to 4 
Cost of RDC Change number of patients per day No RDC (ICER = £22 140) 
  from 2.78 to 3 
Cost of RDC Change number of patients per day No RDC (ICER = £69 969) 
  from 2.78 to 2 
Cost of RDC Change number of patients per day No RDC (ICER = £213 459) 
  from 2.78 to 1 
All costs  Add 20% to all costs No RDC (ICER = £35 678)
All costs  Subtract 20% from all costs No RDC (ICER = £23 786)
All costs  Add 50% to all costs No RDC (ICER = £44 598)
All costs  Subtract 50% from all costs RDC (ICER = £14 866)
Adjusted OR for control After 2 months increase cancer QALY OR No RDC (ICER = £34 848) 
group cancer patients from 0.69 to 0.95
Cancer diagnosis utility Utility decreases by 3% to 0.602 No RDC (ICER = £62 637)
Utility   Keep all utilities 0.664 rather than 0.62 for No RDC (ICER = £245 102) 
  all patients until diagnosis 
Utility   Keep all utilities 0.664 rather than 0.62 for RDC (outperforms) 
  all patients until diagnosis with number of  
  patients 5 per day 
Utility   Keep all utilities 0.664 rather than 0.62 for RDC (outperforms) 
  all patients until diagnosis with number of  
  patients 4 per day 
Utility   Keep all utilities 0.664 rather than 0.62 for No RDC (£182 514)  
  all patients until diagnosis with number of  
  patients 3 per day 
Utility   Keep all utilities 0.664 rather than 0.62 for No RDC (ICER = £576 811)  
  all patients until diagnosis with number of  
  patients 2 per day 
Utility   Keep all utilities 0.664 rather than 0.62 for  No RDC (ICER = £1 759 700) 
  all patients until diagnosis with number of  
  patients 1 per day 
ICER = incremental cost-effectiveness ratio. OR = odds ratio. QALY = quality-adjusted life year. RDC = rapid diagnosis 
centre. WTP = willingness-to-pay.
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Figure 2. Cost-effectiveness acceptability curve 
summarising results of probabilistic sensitivity analysis 
across 1000 runs assuming 2.78 patients per clinic at 
different WTP thresholds. WTP = willingness-to-pay.
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At between 80% and 100% capacity, the RDC 
produces more QALYs and is less costly, and 
thus outperforms standard clinical practice. 
Below 80% capacity, the RDC is not cost-
effective at a £20 000 willingness-to-pay 
threshold. Mean time to diagnosis was 
84.2 days (SD = 65.3) in the control group. 
This was reduced to 5.9 days (SD = 3.4) in 
patients who were diagnosed directly at the 
RDC clinic and to 40.8 days (SD = 30.0) if 
further investigations following RDC were 
warranted.
Strengths and limitations
This analysis is the first to consider the 
cost-effectiveness of an RDC for patients 
with vague and/or non-specific symptoms 
suspicious of cancer in the UK, using a 
relevant control, routine data, and DES. 
DES has proven valid and useful in various 
healthcare settings to model the impact 
of patient pathway changes,8 redesign,10 
and capacity changes.9 However, the 
complexity of the service, patient population, 
and case mix required simplifications and 
assumptions to be made. These were verified 
by RDC key team members. The analysis 
assumes that all RDC staff are present 
throughout, even if the clinic is not at full 
capacity. As this may not accurately reflect 
routine practice, it could overestimate RDC 
implementation cost and underestimate 
cost-effectiveness at lower capacities. 
Detailed information was available for the 
patient pathway after RDC attendance. 
However, it was impossible to track patients 
in the control group who required further 
investigations after their first outpatient 
appointment for which no further patient 
notes were accessible. Therefore, the time 
to diagnosis was assumed to be the time 
to first outpatient appointment, which 
may underestimate time to diagnosis in 
a few cases. Although the impact of this 
omission is likely small, these results may 
still represent a conservative estimate of the 
cost-effectiveness of the RDC.
Furthermore, QoL data were not collected 
routinely as part of the RDC process. Utilities 
had to be extrapolated from the general 
population18 with decrements applied based 
on relative literature values.15–17 Although this 
was deemed the best available approach, 
this amount of data manipulation may have 
introduced bias. However, removing the 
effect of anxiety on patient QoL in sensitivity 
analysis showed that the effect of this 
uncertainty was small and did not change 
the direction of results.
Data used to populate the model were 
taken from the first year of the RDC pilot 
operation. These immature data did not 
allow extrapolation of the longer-term 
impact of the RDC on healthcare resource 
use, patient outcomes, or survival. 
Considering the potential positive effect of 
earlier diagnosis on prognosis, this omission 
will underestimate the cost-effectiveness of 
the RDC. It is therefore planned to extend 
the model to a longer-term time horizon 
as soon as more mature data become 
available.
Comparison with existing literature
Although evaluations of rapid and 
multidisciplinary diagnosis centres are 
currently underway,19 this is the first 
robust and complete analysis of the cost-
effectiveness of the RDC as part of routine 
care in the UK. Also, to the best of the authors’ 
knowledge, no economic evaluations of the 
Danish cancer patient pathway for patients 
presenting with non-specific symptoms and 
signs of cancer (NSSC-CPP), on which the 
UK model of this service is based, exist. 
Considering clinical outcomes, the 
cancer diagnosis rate of 12% in the RDC 
was comparable with conversion rates in 
many site-specific cancer pathways. Urgent 
suspected cancer pathway conversion rates 
were reported to be between a median of 
8.0% and 17.0%,20 and to have a mean of 
11.8%,21 depending on the use of urgent 
pathways, referral rates, and cancer type. 
Also, a recent systematic review and meta-
analysis of fast-track diagnosis of colorectal 
cancer found a cancer detection rate of 
7.7% (confidence interval = 6.9% to 8.5%).22 
Furthermore, the current study's results 
are similar to data from Danish NSSC-CPP 
patients (n = 23 934), which suggest a mean 
cancer diagnosis rate in an RDC setting of 
11% (with values between 9% and 12%).23
Implications for research and practice
Referral to rapid diagnosis services from 
primary care for patients with vague and/
or non-specific symptoms suspicious of 
cancer addresses an important unmet need 
and provides value for money when run near 
or at full capacity. Furthermore, it reduces 
time to diagnosis and has the potential to 
improve patient outcomes. Development of 
a minimum dataset or registry, including 
collection of patient QoL data, should be 
considered to aid any future evaluations of 
the clinical and cost-effectiveness of the 
RDC. Harmonisation of key data items of 
RDC models across the UK and consensus 
on a suitable control in local and national 
contexts will be crucial in any comparisons. 
Using this first model as a template will 
enable further investigation as data mature. 
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